Key Points
- CEO Bassil Dahiyat sold 114,377 shares on December 19 at an average price of $15.71 for about $1.80 million, trimming his stake by 19.69% to 466,635 shares valued at roughly $7.33 million.
- Quarterly results showed a narrower-than-expected loss—EPS of ($0.08) vs. consensus ($0.72), but revenue missed at $21.0 million versus an expected $29.73 million (revenue up 18% year-over-year).
- Analysts remain broadly positive with a consensus rating of "Moderate Buy" and an average price target of $24.88, based on eight Buy, one Hold and one Sell ratings.
Xencor, Inc. (NASDAQ:XNCR - Get Free Report) CEO Bassil Dahiyat sold 114,377 shares of the company's stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $15.71, for a total value of $1,796,862.67. Following the transaction, the chief executive officer directly owned 466,635 shares in the company, valued at $7,330,835.85. The trade was a 19.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Xencor Stock Down 1.5%
Shares of XNCR opened at $15.22 on Friday. The business's fifty day moving average is $15.51 and its 200 day moving average is $11.43. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $24.88. The stock has a market cap of $1.09 billion, a P/E ratio of -8.60 and a beta of 0.96.
Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.64. Xencor had a negative net margin of 87.14% and a negative return on equity of 20.44%. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $29.73 million. During the same quarter in the prior year, the company posted ($0.71) earnings per share. The business's revenue was up 18.0% on a year-over-year basis. On average, analysts expect that Xencor, Inc. will post -3.68 EPS for the current year.
Analyst Ratings Changes
Several equities analysts recently weighed in on the stock. Royal Bank Of Canada raised their price target on shares of Xencor from $18.00 to $19.00 and gave the company an "outperform" rating in a research report on Thursday, November 6th. JPMorgan Chase & Co. dropped their target price on Xencor from $20.00 to $18.00 and set an "overweight" rating on the stock in a report on Thursday, November 6th. Barclays lifted their target price on Xencor from $23.00 to $26.00 and gave the company an "overweight" rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Xencor in a research report on Monday. Finally, Truist Financial started coverage on shares of Xencor in a report on Monday, November 24th. They set a "buy" rating and a $29.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Xencor presently has a consensus rating of "Moderate Buy" and an average price target of $24.88.
Read Our Latest Report on XNCR
Institutional Trading of Xencor
A number of hedge funds have recently bought and sold shares of XNCR. State of Wyoming purchased a new position in Xencor in the first quarter worth $34,000. Hantz Financial Services Inc. raised its stake in shares of Xencor by 209.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company's stock worth $37,000 after purchasing an additional 2,156 shares during the period. GAMMA Investing LLC raised its stake in shares of Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 1,449 shares during the period. Farther Finance Advisors LLC purchased a new position in shares of Xencor in the 3rd quarter worth about $44,000. Finally, Tower Research Capital LLC TRC grew its position in Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 3,018 shares during the period.
Xencor Company Profile
(
Get Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
